ReviewToxins2023
Risk Assessment Considering the Bioavailability of 3-β-d-Glucosides of Deoxynivalenol and Nivalenol through Food Intake in Korea.
Review in Toxins, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Modified Mycotoxins in Food: Current Evidence, Key Uncertainties, and Priorities for Risk Assessment.Comprehensive reviews in food science and food safety · 2026Review
- An Occurrence Study of Mycotoxins in Plant-Based Beverages Using Liquid Chromatography-Mass Spectrometry.Toxins · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deoxynivalenol and nivalenol are major type B trichothecenes and the most frequently occurring mycotoxins worldwide. Their 3-β-d-glucoside forms have recently become a safety management issue. These glucoside conjugates are converted back to the parent toxins during human digestion, but studies to confirm their bioavailability are lacking. In this study, a risk assessment was performed considering the bioavailability of glucoside conjugates. A literature review was conducted to compile the existing bioavailability studies of glucoside conjugates, and three exposure scenarios considering bioavailability were established. As a result of a risk assessment using deterministic and probabilistic methods, both the deoxynivalenol and nivalenol groups had safe levels of tolerable daily intake percentage (TDI%), not exceeding 100%. The TDI% for the nivalenol group was approximately 2-3 times higher than that for the deoxynivalenol group. Notably, infants showed higher TDI% than adults for both toxin groups. By food processing type, the overall TDI% was highest for raw material, followed by simple-processed and then fermented-processed. Since glucoside conjugates can be converted into parent toxins during the digestion process, a risk assessment considering bioavailability allows the more accurate evaluation of the risk level of glucoside conjugates and can direct their safety management in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.